CAS: 261952-04-9; 3-Methyl-5-(Trifluoromethyl)Benzonitrile

上下游产品

CAS号620-22-4 间甲基苯腈

📜间甲基苯腈置于1,10-菲罗啉,(1,5-Cyclooctadiene)(Methoxy)Iridium(I) Dimer,Lithium Hydroxide Monohydrate,Copper(II) Thiophene-2-Carboxylate,4,4'-二叔丁基-2,2'-二吡啶体系中,用 四氢呋喃,二氯甲烷 用作溶剂,化学反应 24.0H,反应生成3-甲基-5-(三氟甲基)苯腈
参考文献:通过铱催化的芳烃硼化对1,3-二取代的芳烃的高选择性三氟甲基化
标题:通过铱催化的芳烃硼化对1,3-二取代的芳烃的高选择性三氟甲基化
摘要:旧的两个描述了铱的连续铱催化的硼化和铜催化的三氟甲基化(参见方案; Pin =频哪醇).该反应在温和的反应条件下进行,并能耐受多种官能团.许多生物活性分子的晚期三氟甲基化证明了这种串联方法的优势.
Doi:10.1002/anie.201106673

专利信息

专利号:US-9303000-B2
优先权日:2011-01-17
标 题 :Olefin containing nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; SHECHTER SHARON; MCCAULEY DILARA
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; SHECHTER SHARON; MCCAULEY DILARA; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

专利号:US-9550757-B2
优先权日:2010-03-05
标题:Nuclear transport modulators and uses thereof
发明人：SHACHAM SHARON; KAUFFMAN MICHAEL; SANDANAYAKA VINCENT P; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

专利号:US-9714226-B2
优先权日:2011-07-29
标题:Hydrazide containing nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; MCCAULEY DILARA; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: n nor a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

专利号:US-9428490-B2
优先权日:2011-07-29
标 题 :Nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.